Certara, the global specialist in model-informed drug development and regulatory science, has acquired BaseCase Management, a data visualisation software as a service (SaaS) company headquartered in Berlin, Germany, with offices in New York
BaseCase, which will join Certara’s Strategic Consulting Services division, has extensive Health Economics and Outcomes Research (HEOR) expertise and is actively working in the area of market access.
As a key element in Certara’s data science portfolio, BaseCase technology will soon be leveraged across the company’s industry-leading pharmacometrics, mechanistic modelling and regulatory science platforms.
The healthcare industry is under increasing pressure to demonstrate the value delivered by new medications and devices.
BaseCase’s interactive platform improves how life science companies communicate and present that value, whether to C-suite executives, physicians and healthcare providers, or payers and health authorities.
This elegant cloud-based solution is ideal for companies seeking to build bespoke, branded apps to deliver impactful communication of complex models, analyses and data.
By integrating content creation with sales enablement, it allows users to quickly create and personalise a visual value proposition around a drug or device’s ROI and business case.
“We are delighted that BaseCase is joining Certara and we are looking forward to expanding the applications for its user-friendly, mobile communications technology. BaseCase simplifies communication of complex data and models,” said Dr Thomas Kerbusch, President of Certara Strategic Consulting Services.
“BaseCase’s interactive platform will enable pharmaceutical and medical technology companies to visualise model results and large, real-world datasets to make sound decisions quickly, within controlled communication cascades,” said Dr Kerbusch.
“The BaseCase team is excited to join Certara and take adoption of our visualisation and communications platform to the next level. We are confident that we are a great match. Both companies have comparable cultures — entrepreneurial, dynamic, diverse and quality driven — and possess a similar mix of scientific and software engineering staff.”
“With the growing acceptance of modeling and simulation in life sciences, comes the need to simplify complex data science concepts and results. Certara is the perfect home for BaseCase,” said BaseCase CEO Dr Gijs Hubben.
“Certara’s extensive software development capability and deep expertise in model-informed drug development will enable us to further accelerate BaseCase’s evolution and growth in this expanding market space,” said BaseCase CTO, Diarmuid Glynn.
“We have already identified several expansion projects that will result from the merger.”
BaseCase technology allows users to easily create content, including embedded data visualisation assets such as spreadsheets, interactive calculators, communications tools and videos within a web browser environment. Extensive graphical design of the platform optimises clarity of communication.
Currently being employed by market access, health economics and IT departments at leading life science companies, the platform includes template tools that facilitate country adaptation of presentations, including translation and localisation.
The perfect marriage between a spreadsheet and a slide show presentation, it allows users to create and distribute mobile apps for customer engagement with a simple drag and drop approach that does not require any coding experience.
Acquisition will add strong visualisation and communications capabilities across Certara’s data science decision-support value chain. Financial details about the transaction were not disclosed.